RE: Meet the FUD-sters24 May 2023 09:00
MyIPA, you are quite right in what you say. The value of this company will be huge in due course. Don't forget that GDR has recently advised the market on revenue numbers moving forwards. In summary this includes in the short term 6-8 UK Hospitals being either "fully operational" or in "approved and beginning implementation" mode with the GDR MT-RNR1 ID Kit.They also confirmed that that the roll out of GDR's MT-RNR1 ID Kit across the UK is worth up to £8.5 million (EACH YEAR), based on approximately 100,000 NICU admissions with an approx customer price per test of £80+.
In the RNS it also stated that the EU market is up to £46.8 million (each and every year), that the U.S. market is worth approx £34 million each year and the rest of the world market equates to £13.8 million every year.
These figures exclude our CYP2C19 ID Stroke Kit, which is targeting the most common type of stroke, which will provide UK revenues for GDR. i.e. £8.5 million to GDR each year (based on approximately 85,000 strokes pa), with EU revenue each year up to £93.5 million (based on 800,000 strokes per year) and even bigger is the U.S. market which is worth up to £67.6 million to GDR every year (based on 700,000 strokes each year). Plus, the rest of the world market is worth £51.0 million EVERY YEAR to GDR.
You only have to read the RNS to understand the huge potential here. The revenue numbers are vast for a company the size of GDR and will easily eventually support a share price in the hundreds of pence and a market cap to match. All we need is patience (and patients)....
Good luck, Brighty
Sign In
Follow the stocks
